一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Cardiology Research >>article

Cardiology Research

IF: 1.39
Download PDF

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.

Published:1 April 2013 DOI: 10.4021/cr270w PMID: 28352420
Hua Ling,?John T Luoma,?Daniel Hilleman

Abstract

Fenofibrate is a third-generation fibric acid derivative indicated as a monotherapy to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B; to increase high-density lipoprotein cholesterol in patients with primary hyperlipidemia or mixed dyslipidemia; and to reduce triglycerides in patients with severe hypertriglyceridemia. In this review, the key characteristics of available fenofibrate formulations are examined. A literature search was conducted, focusing on comparative studies examining bioavailability, food effects, absorption, and lipid efficacy. Fenofibrate is highly lipophilic, virtually insoluble in water, and poorly absorbed. Coadministration with meals was necessary to maximize bioavailability of early formulations. Micronized and nanoparticle formulations of fenofibrate with reduced particle sizes were developed, resulting in greater solubility, improved bioavailability, and in some cases, the ability to be given irrespective of food. A recently introduced hydrophilic choline salt of fenofibric acid also can be taken without regard to meals, is absorbed throughout the gastrointestinal tract, has the highest bioavailability among marketed formulations, and is approved for coadministration with a statin. Differences in bioavailability of fenofibrate formulations have resulted in low-dose (40 - 67) mg and standard-dose (120 - 200 mg) formulations. Different formulations are not equivalent on a milligram-to-milligram basis. In order to prevent medication errors, resulting in underdosing or overdosing with attendant consequences, it is important for healthcare providers to recognize that the formulations of fenofibrate and fenofibric acid that are currently available vary substantially in relation to food effect, equivalency on a milligram-to-milligram basis, and indication to be coadministered with a statin.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Fenofibrate 49562-28-9 C20H21ClO4 784 suppliers $5.00-$602.00
Fenofibric acid 42017-89-0 C17H15ClO4 460 suppliers $5.00-$1500.00
CHOLINE 62-49-7 C5H14NO 91 suppliers $505.54-$505.54

Similar articles

IF:5.4

Desonide: a review of formulations, efficacy and safety.

ACS Applied Energy Materials Nr Kahanek, Cg Gelbard,etc Published: 1 July 2008
外汇| 耒阳市| 哈巴河县| 茌平县| 施甸县| 嵊泗县| 平和县| 故城县| 卢氏县| 八宿县| 普洱| 灵宝市| 陆丰市| 延吉市| 当雄县| 黄浦区| 太仆寺旗| 恩施市| 登封市| 巧家县| 榆林市| 鹤壁市| 溧水县| 永川市| 澄城县| 平谷区| 和田市| 麻阳| 隆林| 金华市| 正镶白旗| 汝南县| 新竹市| 柏乡县| 石渠县| 奈曼旗| 军事| 木里| 苏州市| 青州市| 奇台县|